Literature DB >> 11607879

Androgen secretion in ectopic ACTH syndrome and in Cushing's disease: modifications before and after surgery.

L Barbetta1, C Dall'Asta, T Re, P Colombo, P Travaglini, B Ambrosi.   

Abstract

The role of ACTH in the control of adrenal androgen secretion is known, although the possible existence of other regulatory factors has been also suggested. While some data concerning Cushing's disease have been reported, only few studies concerned androgen levels in ectopic ACTH secretion. The aim of this study was to evaluate serum DHEA-S, androstenedione (A) and testosterone (T) levels in 36 women with ACTH-dependent Cushing's syndrome (30 with Cushing's disease and 6 with ectopic ACTH secretion) before and after surgery. Two men with ectopic ACTH production were also studied. In 30 women with Cushing's disease serum DHEA-S (9.6 +/- 0.9 micromol/l), A (15.2 +/- 1.2 nmol/l) and T (4.1 +/- 0.5 nmol/l) were higher than in controls (p < 0.01): elevated DHEA-S, A and T values were found in 8, 18 and 17 cases, respectively. After adenomectomy in 15 apparently cured patients DHEA-S, A and T levels were low at 1 - 3 months and at 6 - 12 months after surgery. At 18 - 24 months, DHEA-S remained low in spite of cortisol normalisation. In ectopic Cushing's syndrome, A levels were significantly higher (23.1 +/- 4.9 nmol/l) than in Cushing's disease (p < 0.05), while no differences were found in DHEA-S and T levels. Two patients had elevated DHEA-S values, 3 women had high T levels and 7 of the 8 patients had very high A concentration that was lowered in 3 operated cases. In conclusion, the pattern of adrenal androgen secretion is rather different in patients with pituitary or with ectopic Cushing's syndrome. While the frequency of DHEA-S and T alterations is similar, androstenedione secretion is greatly increased in the latter condition. It is suggested that in ACTH-secreting non-pituitary tumours, the production of a POMC-derived peptide, although unidentified, may lead to preferentially stimulated androstenedione secretion, without affecting other enzymatic pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607879     DOI: 10.1055/s-2001-17906

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  Clinical manifestations and hormonal profile of two women with Cushing's disease and mild deficiency of 21-hydroxylase.

Authors:  M Boronat; A Carrillo; A Ojeda; J Estrada; B Ezquieta; F Marín; F J Nóvoa
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 2.  Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Authors:  Hershel Raff; Susmeeta T Sharma; Lynnette K Nieman
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

Review 3.  Effects of Chronic ACTH Excess on Human Adrenal Cortex.

Authors:  Xavier Bertagna
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-08       Impact factor: 5.555

4.  11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing's disease.

Authors:  Hanna F Nowotny; Leah Braun; Frederick Vogel; Martin Bidlingmaier; Martin Reincke; Lea Tschaidse; Matthias K Auer; Christian Lottspeich; Stefan A Wudy; Michaela F Hartmann; James Hawley; Joanne E Adaway; Brian Keevil; Katharina Schilbach; Nicole Reisch
Journal:  Eur J Endocrinol       Date:  2022-09-29       Impact factor: 6.558

5.  Limited Diagnostic Utility of Plasma Adrenocorticotropic Hormone for Differentiation between Adrenal Cushing Syndrome and Cushing Disease.

Authors:  A Ram Hong; Jung Hee Kim; Eun Shil Hong; I Kyeong Kim; Kyeong Seon Park; Chang Ho Ahn; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2015-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.